These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30463993)

  • 1. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions.
    Vazquez SR
    Blood; 2018 Nov; 132(21):2230-2239. PubMed ID: 30463993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions.
    Vazquez SR
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):339-347. PubMed ID: 30504330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T; Gulseth M
    Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug and dietary interactions of the new and emerging oral anticoagulants.
    Walenga JM; Adiguzel C
    Int J Clin Pract; 2010 Jun; 64(7):956-67. PubMed ID: 20584229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically relevant drug interactions between newer antidepressants and oral anticoagulants.
    Spina E; Barbieri MA; Cicala G; Bruno A; de Leon J
    Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):31-44. PubMed ID: 31795773
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation.
    Harskamp RE; Teichert M; Lucassen WAM; van Weert HCPM; Lopes RD
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):615-623. PubMed ID: 31520256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Use of Human Liver Cell Model and Cytochrome P450 Substrate-Inhibitor Panel for Studies of Dasatinib and Warfarin Interactions.
    Zakharyants AA; Burmistrova OA; Poloznikov AA
    Bull Exp Biol Med; 2017 Feb; 162(4):515-519. PubMed ID: 28243904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
    Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
    Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of oral anticoagulants.
    Daly AK; King BP
    Pharmacogenetics; 2003 May; 13(5):247-52. PubMed ID: 12724615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs).
    Gelosa P; Castiglioni L; Tenconi M; Baldessin L; Racagni G; Corsini A; Bellosta S
    Pharmacol Res; 2018 Sep; 135():60-79. PubMed ID: 30040996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments.
    Mega JL; Simon T
    Lancet; 2015 Jul; 386(9990):281-91. PubMed ID: 25777662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Warfarin: pharmacological profile and drug interactions with antidepressants.
    Teles JS; Fukuda EY; Feder D
    Einstein (Sao Paulo); 2012; 10(1):110-5. PubMed ID: 23045839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed de-induction of CYP2C9 compared to CYP3A after discontinuation of rifampicin: Report of two cases
.
    Shibata S; Takahashi H; Baba A; Takeshita K; Atsuda K; Matsubara H; Echizen H
    Int J Clin Pharmacol Ther; 2017 May; 55(5):449-452. PubMed ID: 28157069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Interactions of Direct-Acting Oral Anticoagulants.
    Fitzgerald JL; Howes LG
    Drug Saf; 2016 Sep; 39(9):841-5. PubMed ID: 27435452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does differing metabolism by cytochrome p450 have clinical importance?
    Davidson MH
    Curr Atheroscler Rep; 2000 Jan; 2(1):14-9. PubMed ID: 11122720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
    He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
    Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions.
    Muszkat M; Blotnik S; Elami A; Krasilnikov I; Caraco Y
    Clin Ther; 2007 Mar; 29(3):427-37. PubMed ID: 17577464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy.
    Naganuma M; Shiga T; Nishikata K; Tsuchiya T; Kasanuki H; Fujii E
    J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):363-7. PubMed ID: 11907638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.